On July 10, TransThera Sciences-B rose 8.18% in regular trading, reaching HK$11.11 per share, with turnover of HK$143 million.

On the news front, the company announced on July 1 that its core product Tinengotinib completed patient enrollment for a global multi-center registrational Phase III clinical trial in advanced cholangiocarcinoma, covering over 100 clinical centers across the United States, Europe, and Asia. Tinengotinib is the first and only investigational drug targeting FGFR inhibitor-resistant cholangiocarcinoma to reach the NDA stage globally, having secured FDA Orphan Drug Designation and Fast Track status. Additionally, the company received China NMPA approval to initiate a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody for mantle cell lymphoma treatment.

Within the Biotechnology sector, multiple peers posted strong gains, with PEGBIO CO-B up 39.78%, 3SBIO up 7.06%, REMEGEN up 6.77%, AKESO up 6.08%, and INNOVENT BIO up 4.57%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)